BioLargo, Inc. Discusses 125% Revenue Increase and Significance of Proposed EPA PFAS Regulations with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - March 29, 2023) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO) (the "Company"), a cleantech and life sciences innovator and engineering services solution provider. CEO of the Company, Dennis P. Calvert, joined Stock Day host Everett Jolly.

"We saw your announcement about your 2022 revenues being 125% higher than the previous year. What accounted for such a dramatic increase?", asked Jolly. "We partnered with a group called Ikigai Marketing Works and created a product called Pooph," Calvert explained. "Walmart recently announced that they will be going nationwide with it in Q2," said Calvert, adding that the product is being advertised on television nationally. "Chewy, one of the largest online retailers, has picked it up, along with other retailers."

Calvert elaborated, "We sell our product to them on a wholesale basis and we get a royalty on sales. We also bargained to participate in their equity," he added, noting that the equity agreement is for 20% of the company. "It is a great business model for BioLargo," said Calvert. "This is our number one mover right now, and I think we are just scratching the surface."

"Can you give us an update on your treatment technology for PFAS, also known as 'forever chemicals', in water?", asked Jolly. "Well, the EPA finally came out with the proposed detection limits of four parts per trillion," said Calvert. "With the limits being so low, it expands the scope of the market astronomically, and will include not just drinking water but water used in food production, cosmetics, and other industrial applications," he explained, adding that PFAS chemicals have been linked to birth defects and cancer.

Calvert discussed the Company's own PFAS treatment device, which recently secured its first customer. "To get mass adoption, we need to show full-scale adoption," said Calvert. "We have done about ten trials," he added. "We now have national representation on channel partners, ten agreements have been signed, and we are now getting three to four projects per week proposed to us," shared Calvert. "The pending list of opportunities is worth well over 100 million."

"To our knowledge, we are the only commercially viable technology that makes the claim that it can achieve a non-detect status," continued Calvert. "It is a significant claim, and we have proven it."

Jolly then asked about the Company's recently announced acquisition of a sodium-sulfur battery technology. "One of the co-developers and engineers, who spent five to eight years refining the design to make a sodium-sulfur battery, brought this technology to us," said Calvert. "We acquired the technology and brought the engineer and co-developer to our team, now we are in the replication process for the battery," he explained, adding that the battery is designed to fill a void in the market for safe, long-term fixed site energy storage, like EV charging stations, renewable energy production sites, and grid-scale energy storage.

"Lithium has its drawbacks; it cannot be charged to 100% and cannot be discharged to 0%, it also has a limited functional life," continued Calvert. "We believe we could get a 20-year battery from this with no rare Earth elements, as well as incredible efficiency and a low cost of materials," he explained, adding that the battery also has a much lower risk of runaway fire compared to lithium-ion based technologies which can be highly explosive.

To close the interview Calvert encouraged listeners and shareholders to keep up to date on the Company's current and upcoming projects as they continue to expand and grow an innovative pipeline of technologies.

To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8271999-biolargo-inc-discusses-125-revenue-increase-and-significance-of-proposed-epa-pfas-regulations.

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:
Stock Day Media
(602) 821-1102

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Its core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Its business approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. www.BioLargo.com

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as "we believe". These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo 2022 Annual Earnings Results Webcast and Conference Call on Monday, April 3, 2023 - 4:30 PM Eastern Time

Update - April 6, 2023 - you can review the financial slides from Monday's Earnings Results Webcast right here:

Westminster, CA – March 29, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, will host an investor webcast and conference call on Monday, April 3, 2023, at 1:30 pm Pacific / 4:30 pm Eastern. The event, which will be open to the public, will be held to review the company’s financial results for fiscal year ending December 31, 2022, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:

Webcast Link: https://www.webcaster4.com/Webcast/Page/2448/47877 

Teleconference Domestic: 888-506-0062

Teleconference International: 973-528-0011

Participant Access Code: 857043

To listen to a replay of the teleconference:

Teleconference Replay Expiration: Monday, April 17, 2023

Teleconference Replay Domestic: 877-481-4010

Teleconference Replay International: 919-882-2331

Replay Passcode: 47877

The webcast replay and accompanying presentation materials will be made available for 90 days on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations.  

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.   

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates. 

Proactive Investors Interview: BioLargo acquires sodium-sulfur battery technology to produce new energy solution

Source: Proactive Investors - https://www.proactiveinvestors.com/companies/news/1010078/biolargo-acquires-sodium-sulfur-battery-technology-to-produce-new-energy-solution-1010078.html

BioLargo CEO Dennis Calvert joins Natalie Stoberman from the Proactive studios to share the opportunity behind its acquisition of sodium-sulfur battery energy storage technology.

Calvert says the company has identified this sodium-sulfur battery technology as a high-value solution that has a series of features that set it apart from currently available battery technologies in the market.

BioLargo Acquires Rights to Sodium-Sulfur Battery Energy Storage Technology

Westminster, CA – March 22, 2023 – BioLargo, Inc. (OTCQB:BLGO), a cleantech innovator and full-service environmental engineering company whose products address challenges to environmental and human health, has announced its acquisition of a proprietary sodium-sulfur battery technology. With a strategic focus on advancing technologies that address challenges in the water-energy nexus, the Company has identified this sodium-sulfur battery technology as a high-value solution that has a series of features that set it apart from currently available battery technologies in the market.

BioLargo has formed and secured initial seed capital for BioLargo Energy Technologies, Inc. (“BETI”), a subsidiary designed to address the ongoing shift toward renewable energy production and the growth in global electricity demand, and the consequent drastic expansion in energy storage capacity in the US and world-wide that will be needed to accommodate increased demand and the intermittent nature of renewable energy sources like wind and solar.

BETI will lead the manufacturing, scale-up, and operations for the sodium-sulfur battery technology with the help of one of the technology’s original developers, who has joined BETI. Batteries built based on the underlying technology a decade ago demonstrated features that far surpass comparable lithium-ion batteries, the dominant incumbent technology in the market:

• This sodium-sulfur battery technology demonstrates increased safety, no runaway fire risks, and a more sustainable design – with no rare-earth elements – that is capable of being manufactured completely from the domestic supply chain.
• Unlike lithium-ion batteries, BioLargo’s battery can charge and discharge completely, with no degradation of performance, ensuring virtually unlimited charge/discharge cycles.
• BioLargo’s battery technology also demonstrates increased energy efficiency and energy density in comparison to lithium-ion batteries, and a longer useful life expectancy of at least ten years.

BioLargo’s battery operates at a higher temperature and has relatively heavier casing as compared to lithium-ion batteries, making it well suited for bringing superior performance to stationary applications like electric vehicle charging stations, grid-scale energy storage, and commercial and residential storage.

Randall Moore, President of BioLargo’s engineering subsidiary BioLargo Engineering, Science & Technologies commented, “This battery presents an elegant and realistic solution to the global need for safe, cost-effective long-term energy storage in light of increasingly unstable power grids. The connections our engineering team has fostered over our careers in the energy sector will no doubt be invaluable in our efforts to bring it to market. We believe the features of the battery will compete well against lithium as well as other novel battery technologies.”

BioLargo’s President and CEO Dennis P. Calvert elaborated on the battery’s place in BioLargo’s portfolio of technologies, “It is a natural fit with our other technologies as well as our business model as we invent, prove, and partner our way to commercial success. While we are now enjoying substantial and rising commercial success, which was hard-fought, as our innovation process is and has been continual, like a conveyor belt that keeps moving down the line producing high value solutions to some of the world’s most challenging problems. Much of our specialized work for hire, like our waste-to-energy projects, nuclear fuel handling system design work, as well as our water technologies, all highlight energy efficiency. A safe, sustainable battery energy storage technology is not just a thematic fit for us – it is also a literal fit to complement our work around the world. We are especially thankful to have Mario Caja join our team and lead the effort to prepare the battery for commercialization. And we look forward to working with and through channel partners to commercialize the battery and help transition the world to renewable energy.”

BioLargo's focus on the water-energy nexus – the intersection of water infrastructure and the energy grid – reflects the Company's commitment to creating high-impact solutions that address critical environmental and human wellness challenges. The acquisition of this novel sodium-sulfur battery technology demonstrates the Company's determination to drive positive change while creating value for shareholders.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Continues Record Setting Revenue Growth

Westminster, CA – March 20, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that the Company’s first quarter 2023 revenues have already surpassed the Company’s previous record quarterly revenues set last quarter. This revenue growth is driven primarily by sales of the Pooph branded pet-odor control product sold by Ikigai Marketing Works, LLC. Company management expects that quarter over quarter revenues in Q1 2023 will surpass a 50% growth rate over Q4 2022, will represent the seventh consecutive quarterly period of revenue growth, and that first quarter revenues will be more than four times 2022’s first quarter topline revenue. This comes off the heels of its already released press release dated January 9, 2023, announcing a year over year growth rate of at least 125% for 2022 versus 2021, which represents the eighth consecutive year of revenue growth. While the Company is not yet profitable, its net losses are trending downward as revenues have increased. The Company is currently concluding its audit of its 2022 financial statements and intends to file its annual report with the SEC at the end of March. These revenue estimates for 2022 and the first quarter of 2023 are preliminary and subject to change pending review and audit by the company’s independent registered public accounting firm.

Dennis P. Calvert, President and CEO of BioLargo commented, “The lion’s share of the recent revenue increases is due to the ongoing growth of Pooph sales led by our partners at Ikigai Marketing Works, whom we applaud for their success in expanding the product’s adoption in retail outlets across the country.”

He continued, “We have many products and solutions in early stages of commercialization that we believe will contribute to revenue growth in future periods, such as our PFAS treatment solution, Clyra Medical’s Bioclynse, and Garratt-Callahan’s ‘minimal liquid discharge’ industrial wastewater treatment system. Each of these initiatives continues to advance and we look forward to sharing more information as they each expand. We believe there is still plenty of opportunity for market penetration for the Pooph branded pet-odor control product, as well as the Company’s other products and services.”

The Company intends to hold an earnings conference call and webcast on April 3, 2023 at 1:30 PM Pacific Time. More details will be released prior to that date.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") anticipated revenue and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of global, national and regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo’s PFAS Treatment Technology Meets EPA’s Proposed New Drinking Water Standards

EPA has proposed the first drinking water standards for PFAS “forever chemicals”, paving the way for long-anticipated regulation of PFAS in drinking water. BioLargo’s AEC technology has been proven in multiple case studies to meet or exceed those standards.

Westminster, CA – March 16, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced today that its PFAS treatment system the Aqueous Electrostatic Concentrator (AEC) is capable of treating water to below the EPA’s newly proposed drinking water standards for PFAS.

On March 14, 2023, the Biden-Harris administration announced in a press release that it is proposing long-anticipated national drinking water standards for six PFAS chemicals: PFOA, PFOS, PFNA, PFHxS, PFBS, and GenX. The new rule proposes limits of four parts per trillion for the two most common and widespread PFAS chemicals: PFOA and PFOS. For the other four, they will have a combined, calculated limit weighted by their respective health risks. The White House’s press release is linked here: https://www.epa.gov/newsreleases/biden-harris-administration-proposes-first-ever-national-standard-protect-communities

This move by the EPA, in concert with its September 2023 proposal to designate PFOA and PFOA as CERCLA hazardous substances, is one of the most substantial acts by the Federal Government thus far to regulate PFAS. If finalized after a public comment period, the proposed regulation will require that public water utilities monitor PFAS in their water, notify the public if limits are exceeded, and treat their water to reduce PFAS contamination if it exceeds these limits.

BioLargo’s PFAS treatment technology, the Aqueous Electrostatic Concentrator (AEC), has been proven in multiple case studies, conducted with PFAS-contaminated water provided by municipalities across the US, to reduce each of the six PFAS chemicals targeted by the EPA’s new drinking water standards to below their respective limits of detection, meeting the EPA’s proposed limits. These studies have proven the AEC’s ability to remove all PFAS chemicals monitored in the current testing methods.

Randall Moore, President of BioLargo’s engineering subsidiary, said, “It is especially notable that our AEC technology can reduce the presence of PFBA and PFBS to below their detection limit because existing water treatment solutions like carbon-filtration and ion exchange tend to struggle to remove these. Because of their small size and low polarity, they tend to slip right through carbon and other media-based technologies.”

BioLargo’s President and CEO Dennis P. Calvert commented, “For BioLargo, the timing of this news is perfect. Assuming these regulations go into effect as written, many municipalities will soon be required to install PFAS treatment systems. Our system is the practical, affordable, sustainable solution for all PFAS treatment, generating far less PFAS-laden solid waste than other options. Our team is also being recognized for their expertise on PFAS, with our Director of Commercialization Tonya Chandler being sought after as a speaker at PFAS-focused events many times over the past year.”

He continued, “With our first customer for PFAS treatment already secured and underway – a large industrial site – we are eager to offer our PFAS solution to more municipal and industrial customers over the coming year. As a reminder, we don’t just treat water contaminated with PFAS, we also take on the responsibility of handling their solid waste to make it simple for the customer.”

What are PFAS?

Per- and polyfluoroalkyl substances (PFAS) are a group of harmful chemicals widely used in manufacturing and consumer products, known to contaminate drinking water sources around the world, and are both biopersistent (meaning they remain in organisms indefinitely without breaking down), and are bioaccumulative (meaning that over time, they build up in ever increasing amounts in people, wildlife, aquatic life, and the environment). Having been detected in the blood of more than 99% of tested Americans, they are linked to increased incidence of cancer, liver and kidney disease, reproductive issues, immunodeficiencies, and hormonal disruptions.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") anticipated revenue and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of global, national and regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Sequire Spotlight Presents Biolargo, Inc. (BLGO): Sustainable And Purposeful Innovation

Host Jonathan Miller interviews CEO, Dennis Calvert. He discusses the importance of cleaning forever chemicals out of waterways.

Source: https://microcaps.com/srax-spotlight/sequire-spotlight-presents-biolargo-inc-blgo-sustainable-and-purposeful-innovation/ 

BioLargo Inc., The Pioneering Cleantech Company, Continues To Innovate And Break Down Barriers That Few Thought Was Ever Possible. (Cal Biz Journal Article)

Source: California Business Journal - https://calbizjournal.com/biolargo-inc-the-pioneering-clean-energy-company-continues-to-innovate-and-break-down-barriers-that-few-thought-was-ever-possible/ 

by Craig Landes, Staff Writer, California Business Journal

How does a serial entrepreneur settle into a CEO role that has, so far, spanned over 15 years? By continually building on new ideas, growing new businesses under a larger corporate umbrella, and not hoping for quick wins but planning on them over a span of years.

That’s how Dennis Calvert, CEO of BioLargo, has kept his curiosity and interest in building new entities while staying at the helm of one organization for so long.

The BioLargo origin story goes back to the early 2000’s. After working for several enterprise level companies, Calvert jumped into his first startup at age 27.

“I was one of those kids who walked the neighborhood selling stuff door to door out of my red wagon,” Calvert tells California Business Journal. “Both of my parents were entrepreneurs, so I came by it naturally.”

In 2002, Calvert teamed up with Ken Code, BioLargo’s Chief Science Officer, and Joseph Provenzano, the company’s Senior VP of Operations. “Ken was the inventor who formulated the basic chemistry that became the platform of a number of our products. He had made a discovery about this chemistry and was on a journey to develop products and tools to help keep his dad safe from nosocomial infection in the hospital. That’s how it started.”

So what exactly does BioLargo do?

In a previous article, CBJ focused on BioLargo’s Aqueous Electrostatic Concentrator (AEC), which helps eliminate harmful poly fluoroalkyl substances (PFAS) in drinking water (in addition to wastewater, groundwater, and more). That, in itself, is an important and innovative product with global reach, which just recently secured its first major customer.

But the company is much more than that. BioLargo is also a cleantech company with four units — BioLargo Water, ONM Environmental, BioLargo Engineering, and Clyra Medical. Its last breakthrough product is Pooph, the story of which offers an intriguing case study in how Calvert and the BioLargo team continue to innovate and bring new products and services to market.

Pooph is a pet odor control product manufactured by BioLargo and marketed through a branding company (www.pooph.com). It is sold direct to consumers as well as through retailers like Chewy and Amazon and is currently expanding nationwide at Walmart.

The product is not only effective at eliminating (not covering up) odor, but it is safe to use around pets and humans. This core safety feature of the underlying chemistry is what Code had been working toward thinking about his father for over 20 years. The infomercial video famously features the pitchman spraying Pooph directly into his mouth. It is a product proudly marketed as “safe for people, pets, and the planet,” which fits into BioLargo’s ethos and business philosophy which focuses on sustainability and their stated mission to “make life better”.

While the basic chemical makeup of Pooph has been understood for decades, refining it, supporting its claims with countless case studies, and securing its position as a leading performer in the market took 15 years and millions of dollars. Calvert says BioLargo looks to put products out that are number one in terms of the technology behind them. “And we have to have the data to back up those claims before going to market,” he adds. 

This is the path Calvert looks to take with everything BioLargo is offering. Pooph and AEC are joined by half a dozen other technologies in production or testing.

“The first question we ask: ‘Is this project worthy? Is it worth time and energy? Is it going to be helpful and make the world better? We are a company driven to do something worthy, and if we don’t think it has a chance to be technically number one, then we’re probably not going to do it.’”

Another example of the BioLargo process and tenet is a wound-care and infection control product currently being launched by BioLargo subsidiary Clyra Medical. Already cleared for market under FDA’s 510(k), the product is an antimicrobial technology based on combining compounds that create an oxidative reaction effective against a wide range of disease-causing organisms like viruses, fungi, spores and antibiotic-resistant strains of bacteria while remaining safe and non-toxic.

“It took a fair bit of time and money, and getting the 510(k) clears us up to partner and distribute the product as our first big foray into that market,” Calvert says. “Currently, Clyra is working to secure key partnerships to increase the product’s reach and has more than sixty sales reps targeting hospital systems.”

How can BioLargo’s various products and services work together? When asked about how BioLargo Water might help with water treatment where there are concerns about both biological and chemical contaminations, Calvert had this to say: “None of our big water treatment technologies are simple ‘widgets’ that can be plugged in without customization at a customer site. The larger and more complex the customer site, the more this is true. Usually, treatment of wastewater from, say, a poultry farm, requires what the industry would call a treatment train.”

A treatment train is a series of treatment devices that sequentially removes elements from water, like dissolved solids, then fats and oils, then organic contaminants and bacteria. BioLargo has several technologies that might be used to treat a customer’s problems. For instance, a municipal wastewater treatment plant may need both Advanced Oxidation System (AOS) technology to remove bacteria and micropollutants from water, then the AEC technology to remove PFAS “forever chemicals”, or things like chlorides, from water. “For that reason, we think of our technologies, which target specific market problems, as being very complementary to one another,” Calvert says.

Calvert and the BioLargo team are not finished innovating. Calvert teased several new business sectors that likely will mean a new business or two to run. Meanwhile, Clyra is ramping up its sales operation to handle the market demand, and BioLargo Engineering is helping municipalities and large companies manage the logistics in setting up waste water treatment and large-scale odor control for landfills and other big places that need a massive deodorizing.

“We all want to do something purposeful, important, and worthy,” Calvert concludes. “BioLargo is a realization of that for me and for all of us here. It’s an extension of how we think and believe that we should be operating as corporate citizens.”